top of page
The Professional Network for Healthcare Experts
Oxford BioDynamics signs first pharmaceutical EpiSwitch Orion agreement with Johnson & Johnson
Oxford BioDynamics has secured its first pharmaceutical-company agreement for the EpiSwitch Orion platform, partnering with Johnson & Johnson on inflammatory bowel disease biomarker discovery.
nuaxia
17 hours ago2 min read
AbbVie licenses Nxera oral inflammatory bowel disease drug in agreement worth up to $1.47 billion
AbbVie has secured exclusive worldwide rights to Nxera Pharma's investigational oral EP4 receptor agonist NXE0033744 for inflammatory bowel disease in a licensing agreement potentially worth $1.47 billion.
nuaxia
2 days ago2 min read
FDA approves at-home subcutaneous Skyrizi induction for adults with Crohn's disease
The FDA has approved an at-home subcutaneous induction regimen for AbbVie's Skyrizi in Crohn's disease, offering an alternative to intravenous treatment initiation.
nuaxia
Oct 272 min read
cAMPfield Launches with $180M to Rewire PDE4 Strategy in IBD
cAMPfield Therapeutics has emerged from stealth with $180 million in Series A funding to advance a next-generation oral PDE4 inhibitor targeting inflammatory bowel disease (IBD), a space where earlier drugs have struggled due to tolerability limitations.
nuaxia
Jun 223 min read
bottom of page